United Therapeutics Corporation has announced the launch of the first-ever human clinical trial of a xenotransplantation intended to support potential registration through a Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA). The FDA has approved the company’s Investigational New Drug (IND) application to begin the study. The trial will evaluate UKidney, … A Win for Transplant Medicine — FDA IND Approval for Gene-Edited Pig Kidney Clinical Trial Read More » To access this post, you must purchase Individual Subscriber Yearly or Enterprise Subscriber.